Synovics Pharmaceuticals Stock Probability of Future Stock Price Finishing Over 1.0E-4
| SYVC Stock | USD 0.0001 0.00 0.00% |
Synovics Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Synovics Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Synovics Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Synovics Pharmaceuticals generated a negative expected return over the last 90 days | |
| Synovics Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Synovics Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Synovics Pharmaceuticals currently holds 2.1 M in liabilities. Synovics Pharmaceuticals has a current ratio of 0.26, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Synovics Pharmaceuticals' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 25.96 M. Net Loss for the year was (4.01 M) with profit before overhead, payroll, taxes, and interest of 4.47 M. | |
| Latest headline from news.google.com: 270,284 traded Tengion volume spike 28 Jan 2026 liquidity is key - Meyka |
Synovics Pharmaceuticals Technical Analysis
Synovics Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Synovics Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Synovics Pharmaceuticals. In general, you should focus on analyzing Synovics Stock price patterns and their correlations with different microeconomic environments and drivers.
Synovics Pharmaceuticals Predictive Forecast Models
Synovics Pharmaceuticals' time-series forecasting models is one of many Synovics Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Synovics Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Synovics Pharmaceuticals
Checking the ongoing alerts about Synovics Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Synovics Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Synovics Pharmaceuticals generated a negative expected return over the last 90 days | |
| Synovics Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Synovics Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Synovics Pharmaceuticals currently holds 2.1 M in liabilities. Synovics Pharmaceuticals has a current ratio of 0.26, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Synovics Pharmaceuticals' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 25.96 M. Net Loss for the year was (4.01 M) with profit before overhead, payroll, taxes, and interest of 4.47 M. | |
| Latest headline from news.google.com: 270,284 traded Tengion volume spike 28 Jan 2026 liquidity is key - Meyka |
Check out Synovics Pharmaceuticals Analysis, Synovics Pharmaceuticals Valuation, Synovics Pharmaceuticals Correlation, Synovics Pharmaceuticals Hype Analysis, Synovics Pharmaceuticals Volatility, Synovics Pharmaceuticals Price History as well as Synovics Pharmaceuticals Performance. For information on how to trade Synovics Stock refer to our How to Trade Synovics Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Will Pharmaceuticals sector continue expanding? Could Synovics diversify its offerings? Factors like these will boost the valuation of Synovics Pharmaceuticals. If investors know Synovics will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Synovics Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Synovics Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Synovics's accounting equity. The concept of intrinsic value - what Synovics Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Synovics Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Synovics Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Synovics Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Synovics Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.